Peginterferon Beta-1A
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Peginterferon beta-1a: From Multiple Sclerosis to Heart Neoplasm
One-Sentence Summary
Peginterferon beta-1a (internationally marketed as Plegridy) is a pegylated interferon beta-1a normally used for relapsing forms of multiple sclerosis. The TxGNN model predicts a possible signal for Heart Neoplasm (score 94.10%), but this is currently a model-prediction-only finding — 0 clinical trials and 0 publications were found for this drug-disease pair, and the drug itself is not marketed/authorized in this jurisdiction (0 licenses on file).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack — no licenses/indication text on file. (Externally known use: relapsing forms of multiple sclerosis, marketed as Plegridy) |
| Predicted New Indication | Heart Neoplasm |
| TxGNN Prediction Score | 94.10% |
| Evidence Level | L5 |
| Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the evidence pack (flagged as data gap DG002, High severity). Based on general pharmacological knowledge, peginterferon beta-1a is a PEGylated form of interferon beta-1a, an immunomodulatory cytokine that reduces immune-mediated inflammation and demyelination in the central nervous system — this is the basis for its approved use in multiple sclerosis. It has no established antineoplastic or cardiac-targeted mechanism.
The link between multiple sclerosis (an autoimmune neurological disease) and heart neoplasm (a rare structural/cardiac tumor) is not mechanistically obvious. The predicted rationale draws an indirect analogy to interferon-alpha, a related but distinct interferon class with documented antiproliferative use in some vascular tumors (e.g., infantile hemangioma). However, no preclinical or clinical data specifically link peginterferon beta-1a to cardiac tumor biology — the connection here is a knowledge-graph embedding similarity, not a validated pharmacological hypothesis.
Given the complete absence of supporting clinical trials or literature (confirmed by 0 hits across ClinicalTrials.gov, ICTRP, and PubMed queries), this prediction should be treated as an early-stage hypothesis only, appropriate for the L5 / S0 (model-prediction-only) evidence tier assigned by the scoring system.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
This drug is not currently marketed or authorized in this jurisdiction — there are 0 licenses on file, and no authorization number, product name, dosage form, or approved indication text is available in the evidence pack.
Safety Considerations
Safety data collection is currently blocked: label warnings and contraindications could not be retrieved (data gap DG001, Blocking severity — no TFDA label/SmPC data parsed yet), and no drug-interaction data was found (query status: not found). This gap prevents the candidate from advancing to the S1 preliminary safety screening stage.
Please refer to the SmPC for safety information once available.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate sits at evidence level L5 (model prediction only) with zero clinical trials or publications across all 10 top-ranked predicted indications, and a Blocking-severity data gap (missing label safety data) prevents even a preliminary safety screen. Several other top-ranked predictions for this drug — notably heart conduction disease (rank 3) and pericardium disease (rank 10) — are plausibly explained by reversed causality: interferon-beta is a known cause of cardiac conduction abnormalities and pericarditis as adverse drug reactions, not a treatment for them, which raises signal-quality concerns for this entire drug-disease cluster rather than supporting the top prediction.
To proceed, the following is needed:
- TFDA/SmPC label data — warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action (DG002)
- Independent preclinical or clinical evidence of interferon beta-1a activity in cardiac neoplasms specifically (not extrapolated from interferon-alpha)
- Causal-direction review of KG-derived predictions that overlap with known adverse drug reactions (heart conduction disease, pericardium disease) before any further evaluation
⚠️ Note on Other Top-Ranked Candidates
Beyond the primary prediction, ranks 4–9 (borderline ovarian serous tumor, rete ovarii cystadenoma, ovarian mucinous cystadenofibroma, ovarian benign neoplasm, ovarian papillary cystadenoma, malignant ovarian Brenner tumor) form a tight score cluster (88.0–88.9%) of largely benign/rare ovarian entities with no clinical treatment precedent for systemic immunomodulatory therapy — this pattern is more consistent with knowledge-graph node clustering around “ovarian tumor” concepts than with distinct pharmacological signals. None of these carry clinical trial or literature support either. All 10 candidates for this drug are recommended for Hold pending the data-gap remediation above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.